The Community Oncology Alliance (COA) recently released the “OCM 2.0,” an innovative and ambitious reform model to improve quality, reduce costs, and provide important additional cancer care services to patients.  Not your typical alternative payment model (APM), the OCM 2.0 includes bold proposals for value-based drug contracts that, if implemented, would provide high-quality, coordinated oncology

Personalized medicine holds tremendous promise for changing the way cancer is treated, but this promise has only been realized for a handful of mutations in a handful of cancers. Several factors have been blamed for why this is the case, and one of them is the limited insurance coverage of next generation sequencing (NGS).

A possible universal model of oncology payment reform building on the Oncology Care Model (OCM), COA’s proposed 'OCM 2.0' addresses several issues identified by current participants, and how value-based payments might be incorporated in the future. COA hosted this webinar on January 9th to provide details on the development of the OCM 2.0 and COA’s

On Thursday, November 16th the Community Oncology Alliance (COA), Florida Cancer Specialists & Research Institute (FCS), and Oncology Business Review (OBR) hosted a free webinar to discuss recent research into the cost differences between hospitals and community oncology practices, and how public policy can be changed to address it. Results of a recent study